Henry Schein recently announced a $250 million investment from KKR, strengthening its financial position and strategic initiatives. With this investment, KKR will become Henry Schein’s largest non-index fund shareholder, increasing its stake to 12%, with the potential to expand to 14.9% through market purchases.
As part of the agreement, Max Lin and William K. “Dan” Daniel from KKR, along with Robert J. Hombach, have been appointed to Henry Schein’s board of directors. Their expertise in healthcare, finance, and operations is expected to contribute to the company’s long-term growth.
Henry Schein also reported preliminary financial results for 2024, with $12.7 billion in annual revenue and $3.05 GAAP EPS. Non-GAAP EPS stood at $4.74, reflecting strong operational performance.
For 2025, the company forecasts low- to mid-single-digit revenue and earnings growth, driven by strategic investments and efficiency initiatives.
Additionally, Henry Schein’s board of directors has authorized an additional $500 million share repurchase program, with $250 million allocated to accelerated buybacks.
Click here to see the full press release for more information.
